Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOTABLE-308: Nimotuzumab + Trifluridine/Tipiracil in mCRC
NCT06343116Phase 3Withdrawn
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of nimotuzumab in colorectal cancer (CRC). Planned start Apr 2024; status: withdrawn.
02
Drugs
nimotuzumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06343116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06343116.